Agents antiangiogéniques et association de TMC: attention danger

Greater knowledge in cancer biology has led to the isolation of molecular targets implicated in cell physiology. New treatments blocking a specific molecular target, in particular compounds blocking kinase activity, which play a key role in the transmission of the proliferation or angiogenesis signal, called molecular targeted therapies (MTTs), have shown benefit for several tumors and now are widely used including oral small molecules and monoclonal antibodies. Nevertheless, MTTs can inhibit major pathways in normal or non cancerous cells leading to unexpected off-target side effects, morbidity, reduced drug doses or even drug cessation. The combination of anti-angiogenic therapies with other MTTs could be challenging because of drug interactions or side effects.